Sep 17, 2012
On September 12, the FDA approved the teriflunomide (brand name Aubagio®) treatment for relapsing forms of MS. This treatment was developed by Genzyme, a Sanofi company. This is the second oral disease-modifying therapy approved for the treatment of multiple sclerosis. Like the other disease modifying treatments available for MS, this therapy targets cells of the immune system in order to prevent or slow down attacks on the brain. The therapy is expected to be available for prescription by October 1, 2012 in the U.S. While we are thrilled that a new oral drug is available for relapsing MS, we remain relentlessly focused on addressing the needs of those affected by progressive forms of MS. With the collaborative research underway around the world today, we are optimistic that rapid progress will be made to bring new treatment options for progressive MS.